Characterization and treatment of persistent hepatocellular secretory failure-Reference-Cited by-同舟云学术

Characterization and treatment of persistent hepatocellular secretory failure

Published:2014-07-04 Issue:4 Volume:35 Page:1478-1488
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

van Dijk Remco¹,Kremer Andreas E.¹²,Smit Wouter¹,van den Elzen Bram¹,van Gulik Thomas³,Gouma Dirk³,Lameris Johan S.⁴,Bikker Hennie⁵,Enemuo Valentine⁶,Stokkers Pieter C. F.⁷,Feist Mark⁸,Bosma Piter¹,Jansen Peter L. M.¹,Beuers Ulrich¹

Affiliation:

1. Department of Gastroenterology & Hepatology and Tytgat Institute for Liver and Intestinal Research; Academic Medical Centre; University of Amsterdam; Amsterdam The Netherlands

2. Department of Medicine I; Friedrich-Alexander-University of Erlangen-Nuremberg; Erlangen Germany

3. Department of Surgery; Academic Medical Centre; University of Amsterdam; Amsterdam The Netherlands

4. Department of Radiology; Academic Medical Centre; University of Amsterdam; Amsterdam The Netherlands

5. Department of Clinical Genetics; Academic Medical Centre; University of Amsterdam; Amsterdam The Netherlands

6. Department of Pediatric Gastroenterology; Louisiana State University Health Sciences Centre; New Orleans LA USA

7. Department of Gastroenterology and Hepatology; St Lucas Andreas Hospital; Amsterdam The Netherlands

8. Department of Pediatric Gastroenterology; Medical Office Building; Lubbock TX USA

Funder

Deutsche Crohn-Colitis-Vereinigung

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12603/fullpdf

Reference35 articles.

1. Management of cholestatic liver diseases;EASL Clinical Practice Guidelines;J Hepatol,2009

2. Primary biliary cirrhosis;Lindor;Hepatology,2009

3. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis;Beuers;Nat Clin Pract Gastroenterol Hepatol,2006

4. Nuclear receptors as therapeutic targets in cholestatic liver diseases;Zollner;Br J Pharmacol,2009

5. Molecular targets for the treatment of fibrosing cholangiopathies;Maillette de Buy Wenniger;Clin Pharmacol Ther,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclosporine-A induced cytotoxicity within HepG2 cells by inhibiting PXR mediated CYP3A4/CYP3A5/MRP2 pathway;Drug and Chemical Toxicology;2024-01-03

2. Identifying chemicals based on receptor binding/bioactivation/mechanistic explanation associated with potential to elicit hepatotoxicity and to support structure activity relationship-based read-across;Current Research in Toxicology;2023

3. Advances in understanding the regulatory mechanism of organic solute transporter α-β;Life Sciences;2022-12

4. A historical review of jaundice: May the golden oriole live forever;Clinical Liver Disease;2022-11

5. Case Report: A Rare Heterozygous ATP8B1 Mutation in a BRIC1 Patient: Haploinsufficiency?;Frontiers in Medicine;2022-06-16